Search - tctmd.com

Displaying 141 - 160 of 168

Sort: Relevancy | Date

Presentation

Influence of Genetic Polymorphisms on High- and Standard-Dose Clopidogrel After PCI

Presenter: Matthew J. Price

May 22, 2012

Presentation

A Randomized Trial of Prasugrel vs. Clopidogrel in Patients with High Platelet Reactivity on Clopidogrel After Elective PCI with DES

Presenter: Dietmar Trenk

April 18, 2012

Presentation ACC 2012

RESET Study: Pharmacodynamic Effects of Switching Therapy in PCI Patients with High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose versus Prasugrel

Presenter: Gennaro Sardella

March 24, 2012

Presentation ACC 2012

First Pharmacogenomic Analysis Using Whole Exome Sequencing to Identify Novel Genetic Determinants of Clopidogrel

Presenter: Matthew Price

March 24, 2012

Presentation ACC 2012

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Presenter: Hyo-Soo Kim

March 24, 2012

Presentation

El Tabaquismo se asocia a un Efecto Dosis-Respuesta en Pacientes tratados con Clopidogrel con Diabetes Mellitus y EAC

Presenter: M. Ueno

March 19, 2012

Presentation

Cigarette Smoking Associated with a Dose-Response Effect in Clopidogrel-Treated Patients with Diabetes Mellitus and CAD

Presenter: M. Ueno

March 19, 2012

Presentation

Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing CABG

Presenter: E. Mahla

March 13, 2012

Presentation

Estrategia basada en Medir la Función Plaquetaria para Reducir las Hemorragias en el Tiempo de Espera en Pacientes Tratados con Clopidogrel que se someten a un CABG

Presenter: E. Mahla

March 13, 2012

Presentation

Impacto de la Anemia en la Respuesta Plaquetaria al Clopidogrel en Pacientes sometidos a PCI

Presenter: C. Toma

February 14, 2012

Presentation

Impact of Anemia on Platelet Response to Clopidogrel in Patients Undergoing PCI

Presenter: Catalin Toma

February 14, 2012

Presentation

¿Existe una Interacción Clínica Significativa Entre los Bloqueadores de los Antagonistas de los Canales del Calcio y Clopidogrel?

Presenter: Christopher W. Good

February 12, 2012

Presentation

Is There a Clinically Significant Interaction Between Calcium Channel Antagonists and Clopidogrel?

Presenter: Christopher W. Good

February 12, 2012

Presentation

Association of PPI Use and Cardiovascular Outcomes with Clopidogrel and Ticagrelor

Presenter: Shaun G. Goodman

January 24, 2012

Presentation

Relaciones entre el uso de IBP y Desenlaces Cardiovasculares con Clopidogrel y Ticagrelor

Presenter: Shaun G. Goodman

January 24, 2012

Presentation

CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events

Presenter: Michael V. Holmes

January 04, 2012

Presentation TCT 2012

The impact of paraoxonase-1 activity on the incidence of intra-stent thrombus after drug-eluting stent implantation in the Japanese CYP2C19*2 carriers receiving clopidogrel

Presenter: Ryo Nishio, Junya Shite, Toshiro Shinke, Hiromasa Otake, Masayuki Nakagawa, Ryoji Nagoshi, Amane Kozuki, Takumi Inoue, Hirotoshi Hariki, Tsuyoshi Osue, Yu Taniguchi, Masamichi Iwasaki, Noritoshi Hiranuma, Akihide Konishi, Hiroto Kinutani, Yoko Haraguchi, Tatsuro Ishida, Ken-ichi Hirata

January 03, 2012

Presentation TCT 2012

The Association Between Duration of Clopidogrel Therapy After Saphenous Vein Graft Intervention And Long-Term Death And Myocardial Infarction

Presenter: Amit Sachdeva, Sumati Bavisetty, Gerald Beckham, Vicken Aharonian, Prakash Mansukhani, Gregg W. Stone, Naing Moore, Ric Hyett, Richard Contreras, Somjot S. Brar

January 03, 2012

Presentation TCT 2012

Stopping Clopidogrel 1 year After Drug-Eluting Stent (DES) Implantation: Is It Safe?

Presenter: Nalyaka Sambu, Hazel Dent, Timothy Warner, Nicola Englyst, Philip Leadbeater, Alex Hobson, Alison Calver, Simon Corbett, Huon Gray, Iain Simpson, John Morgan, Nick Curzen

January 03, 2012

Presentation TCT 2012

Protease Activated Receptor-1 (PAR-1) Mediated Platelet Aggregation is Dependant on Clopidogrel Response

Presenter: Rolf P. Kreutz, David A. Flockhart, Yvonne Kreutz, Jeffrey A. Breall

January 03, 2012

Advertisement

Influence of Genetic Polymorphisms on High- and Standard-Dose Clopidogrel After PCI

A Randomized Trial of Prasugrel vs. Clopidogrel in Patients with High Platelet Reactivity on Clopidogrel After Elective PCI with DES

RESET Study: Pharmacodynamic Effects of Switching Therapy in PCI Patients with High on Treatment Platelet Reactivity and Genotype Variation: High Clopidogrel Dose versus Prasugrel

First Pharmacogenomic Analysis Using Whole Exome Sequencing to Identify Novel Genetic Determinants of Clopidogrel

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

El Tabaquismo se asocia a un Efecto Dosis-Respuesta en Pacientes tratados con Clopidogrel con Diabetes Mellitus y EAC

Cigarette Smoking Associated with a Dose-Response Effect in Clopidogrel-Treated Patients with Diabetes Mellitus and CAD

Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing CABG

Estrategia basada en Medir la Función Plaquetaria para Reducir las Hemorragias en el Tiempo de Espera en Pacientes Tratados con Clopidogrel que se someten a un CABG

Impacto de la Anemia en la Respuesta Plaquetaria al Clopidogrel en Pacientes sometidos a PCI

Impact of Anemia on Platelet Response to Clopidogrel in Patients Undergoing PCI

¿Existe una Interacción Clínica Significativa Entre los Bloqueadores de los Antagonistas de los Canales del Calcio y Clopidogrel?

Is There a Clinically Significant Interaction Between Calcium Channel Antagonists and Clopidogrel?

Association of PPI Use and Cardiovascular Outcomes with Clopidogrel and Ticagrelor

Relaciones entre el uso de IBP y Desenlaces Cardiovasculares con Clopidogrel y Ticagrelor

CYP2C19 Genotype, Clopidogrel Metabolism, Platelet Function, and Cardiovascular Events

The impact of paraoxonase-1 activity on the incidence of intra-stent thrombus after drug-eluting stent implantation in the Japanese CYP2C19*2 carriers receiving clopidogrel

The Association Between Duration of Clopidogrel Therapy After Saphenous Vein Graft Intervention And Long-Term Death And Myocardial Infarction

Stopping Clopidogrel 1 year After Drug-Eluting Stent (DES) Implantation: Is It Safe?

Protease Activated Receptor-1 (PAR-1) Mediated Platelet Aggregation is Dependant on Clopidogrel Response

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content